Open AccessDidymin Alleviates Hepatic Fibrosis Through Inhibiting ERK and PI3K/Akt Pathways via Regulation of Raf Kinase Inhibitor Protein
Author(s) -
Xiaobo Lin,
Faicheng Bai,
Jinlan Nie,
Sheng Lu,
Chunyuang Lu,
Xunshuai Zhu,
Jinbin Wei,
Zhaojun Lu,
Quanfang Huang
Publication year - 2016
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000453194
Subject(s) - protein kinase b , pi3k/akt/mtor pathway , mapk/erk pathway , protein kinase a , cancer research , kinase , microbiology and biotechnology , fibrosis , signal transduction , p38 mitogen activated protein kinases , chemistry , hepatic fibrosis , pharmacology , medicine , biology
Didymin has been reported to have anti-cancer potential. However, the effect of didymin on liver fibrosis remains illdefined.